DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0302415 A1 Lulla Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0302415 A1 Lulla Et Al US 2013 0302415A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0302415 A1 Lulla et al. (43) Pub. Date: Nov. 14, 2013 (54) PHARMACEUTICAL COMPOSITION (30) Foreign Application Priority Data (71) Applicant: CIPLA Limited, Mumbai (IN) Apr. 20, 2010 (IN) ......................... 1296/MUMA2010 (72) Inventors: Amar Lulla, Mumbai (IN); Geena Publication Classification Malhotra, Mumbai (IN) (51) Int. Cl. 469/14 (2006.01) (21) Appl. No.: 13/941,525 A613 L/536 (2006.01) (52) U.S. Cl. 1-1. CPC ................. A61 K9/14 (2013.01); A61 K3I/536 USPC ........ 424/451; 428/402: 424/489: 514/230.5; Related U.S. Application Data 424/464 (63) Continuation of application No. 13/641,852, filed as (57) ABSTRACT application No. PCT/GB2011/000620 on Apr. 20, A pharmaceutical composition comprising efavirenz wherein 2011. the efavirenz is in the form of nanoparticles is disclosed. Patent Application Publication Nov. 14, 2013 US 2013/0302415 A1 - Efavirenz and -... rior art fine (mins) warrawasarasaarerracalarrawlexxxx-exax-da Figure 1 US 2013/0302415 A1 Nov. 14, 2013 PHARMACEUTICAL COMPOSITION drugs are not completely released in gastro intestinal tract area, they have low bioavailability. Thus, there is a need to CROSS-REFERENCE TO RELATED CASES increase the therapeutic dose of the drug in order to obviate this disadvantage; however increasing the dose may lead to 0001. This application is filed under 35 U.S.C. S.1.11(a) as a continuation application which claims priority under 35 increase in the side effects of the drug. U.S.C. S 119, 35 U.S.C. S 120, and the Patent Cooperation 0007 Various prior art formulations have been reported to Treaty to: parent application U.S. Ser. No. 13/641,852 filed improve the solubility of the efavirenz in the GI tract. For under 35 U.S.C. S371 on Oct. 17, 2012; which claims priority example, one of the approaches used is encapsulation of drug to PCT/GB2011/000620 filed under the authority of the in cyclodextrins using 1:1 molar ratio as reported by Indrajit Patent Cooperation Treaty on Apr. 20, 2011, published; which etal in Macromolecular symposia in 2010, 287,51-59. How claims priority to Indian Application Ser. No. 1296/MUM/ ever considering the high dose of efavirenz, it is practically 2010 filed Apr. 20, 2010. difficult to develop oral dosage form using cyclodextrins. 0008 Solid dispersion and PEGylation techniques have FIELD OF INVENTION also been proposed by Madhavietal in “Dissolution enhance ment of efavirenz by solid dispersion and PEGylation tech 0002 The present invention relates to a pharmaceutical niques'. International Journal of Pharmaceutical Investiga composition comprising an antiretroviral drug, a process for tion, 2011 (1), 29-34, wherein the drug and the carrier are preparing Such composition, therapeutic uses and method of added to a common solvent followed by homogenization and 5 treatment employing the same. evaporation of the solvent to form solid dispersion of efavirenz. However recrystallization of amorphous solid dis BACKGROUND & PRIOR ART persions due to temperature, humidity, and the amount of 0003. Efavirenz is the international non-proprietary name polymer may lead to a reduction in the dissolution rate, and for non-nucleoside reverse transcriptase inhibitor (S)-6- consequently reduce bioavailability. Further the article also chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihy states that drug-PEG conjugates in 1:1 and 1:2 w/w ratios dro-2H-3,1-benzoxazin-2-one belonging to class of benzox were prepared by dissolving efavirenz and PEG 6000 sepa azinones. Efavirenz has the following structural formula: rately in organic solvent and then pouring the solution of the drug into the solution of PEG while stirring, incubating the mixture overnight and then evaporating the solvent to yield the PEGylated compound. However PEGylation is a complex procedure requiring many processing steps. 0009 WO99/61026 discloses a tablet dosage form of efavirenz, wherein lactose is added extragranularly to obtain a stable tablet formulation which is bioequivalent to the capsule formulation of efavirenz. However, the patent does not pro vide any bioeduivalence data. (0010 U.S. Pat. No. 6,555,133 B2 provides improved oral dosage forms of efavirenz containing one or more Super dis integrants that enhance the dissolution rate of the drug in the gastrointestinal tract thereby improving the rate and extent of 0004 Efavirenz is effective in the treatment of the human absorption of drug in the body. However use of higher amount immunodeficiency virus (HIV) which is the retrovirus that of a Super disintegrant like Sodium starch glycolate may lead causes progressive destruction of the human immune system to a negative effect on the disintegration of the tablets due to resulting in onset of AIDS. Efavirenz is a highly potent formation of a viscous gel layer formed by Sodium starch reverse transcriptase inhibitor and is effective against HIV glycolate that may form a thick barrier to the further penetra reverse transcriptase resistance. It is a crystalline lipophilic tion of the disintegration medium and hinder the disintegra solid with a log octanol water partition coefficient of 5.4 and tion of tablets Development of Fast Dispersible Aceclofenac an aqueous solubility of 9.0 ug/ml. Tablets: Effect of Functionality of Superdisintegrant, C. Mal 0005 Efavirenz is classified in class II drugs (low solubil likarjuna Setty and etal; Received Feb. 7, 2007: Revised Jan. ity, high permeability) of the Biopharmaceutical Classifica 16, 2008: Accepted Mar. 12, 2008 tion System. Class II drugs like efavirenz demonstrate poor 0011. Therefore, the improvement of efavirenz solubility gastrointestinal (GI) absorption due to inadequate drug solu thereby its oral bio-availability while reducing the dose of bility in GI fluids. Furthermore, efavirenz is a crystalline drug remains one of most challenging aspects especially for lipophilic solid with an aqueous solubility of 9.0 ug/mL and oral drug delivery system. It is desirable to provide compo with a low intrinsic dissolution rate (IDR) of 0.037 mg/cm sitions of efavirenz exhibiting enhanced bioavailability com 2/min. The drugs with less than 0.1 mg/cm2/min of IDR have pared to the prior art formulations. Thus there still exists an dissolution as a rate-limiting step in absorption, which is unmet need to develop an efavirenz formulation with further affected by the fed/fasted state of the patient. This in improved solubility and dissolution properties of the drug. turn can affect the peak plasma concentration, making calcu lation of dosage and dosing regimens more complex. OBJECT OF THE INVENTION 0006. This suggests the importance of dissolution improvement for efavirenz. Moreover, most of these new 0012. The object of the present invention is to provide a chemical entities despite their high permeability, are only pharmaceutical composition of efavirenz having improved absorbed in the upper Small intestine. Consequently, if these solubility and dissolution. US 2013/0302415 A1 Nov. 14, 2013 0013 Another object of the present invention is to provide tion top-down technology. Different methods may be uti a method of manufacturing a pharmaceutical composition lized to reduce the particle size of the hydrophobic drugs for comprising efavirenz. ex: Huabing Chen and etal, discusses the various methods to develop nanoformulations in “Nanonization strategies for SUMMARY OF THE INVENTION poorly water-soluble drugs. Drug Discovery Today, Volume 00, Number 00, March 2010. 0014. According to one aspect of the invention there is 0024. The nanoparticles of the present invention may be provided a composition comprising efavirenz in the form of obtained by any of the process such as but not limited to particles, wherein Substantially all the particles have a par milling, precipitation and homogenization. ticle size less than or equal to 1 micrometre. 0025. According to one embodiment of the present inven 0015. In a preferred embodiment, the composition further tion, the process of milling comprises dispersing efavirenz comprises at least one Surface stabilizer, at least one viscosity particles in a liquid dispersion medium in which efavirenz is building agent and at least one polymer, wherein Substantially poorly soluble, followed by applying mechanical means in all the particles have a particle size less than or equal to 1 the presence of grinding media like milling pearls to reduce micrometre. the particle size of efavirenz to the desired average particle 0016. In a preferred embodiment, all the particles have a S17C. particle size above 1 nanometre. 0026. According to another embodiment of the present 0017. The composition described above may comprise a invention, the process of precipitation involves the formation pharmaceutical composition, or may be used to form a phar of crystalline or semi-crystalline efavirenz, nanoparticles by maceutical composition. nucleation and the growth of drug crystals. In a typical pro 0018. According to another aspect of the present invention cedure, drug molecules are first dissolved in an appropriate there is provided a pharmaceutical composition comprising organic solvent Such as acetone, tetrahydrofuran or N-me efavirenz or a pharmaceutically acceptable salt, Solvate, thyl-2-pyrrolidone at a Super Saturation concentration to derivative, hydrate, polymorph, or mixtures thereof wherein allow for the nucleation of drug seeds. Drug nanocrystals are the particle size of efavirenz is in nanometre range. then formed by adding the organic mixture to an antisolvent 0019. According to yet another aspect of the present like water in the presence of stabilizers such as Tween 80, invention there is provided a process for preparing a pharma Poloxamer 188 or lecithin. The choice of solvents and stabi ceutical composition comprising efavirenz or a pharmaceu lizers and the mixing process are key factors to control the tically acceptable salt, Solvate, derivative, hydrate, poly size and stability of the drug nanocrystals. morph, or mixtures thereof wherein the particle size of 0027.
Load more

Recommended publications
  • Sodium Dodecyl Sulfate
    Catalog Number: 102918, 190522, 194831, 198957, 811030, 811032, 811033, 811034, 811036 Sodium dodecyl sulfate Structure: Molecular Formula: C12H25NaSO4 Molecular Weight: 288.38 CAS #: 151-21-3 Synonyms: SDS; Lauryl sulfate sodium salt; Dodecyl sulfate sodium salt; Dodecyl sodium sulfate; Sodium lauryl sulfate; Sulfuric acid monododecyl ester sodium salt Physical Appearance: White granular powder Critical Micelle Concentration (CMC): 8.27 mM (Detergents with high CMC values are generally easy to remove by dilution; detergents with low CMC values are advantageous for separations on the basis of molecular weight. As a general rule, detergents should be used at their CMC and at a detergent-to-protein weight ratio of approximately ten. 13,14 Aggregation Number: 62 Solubility: Soluble in water (200 mg/ml - clear, faint yellow solution), and ethanol (0.1g/10 ml) Description: An anionic detergent3 typically used to solubilize8 and denature proteins for electrophoresis.4,5 SDS has also been used in large-scale phenol extraction of RNA to promote the dissociation of protein from nucleic acids when extracting from biological material.12 Most proteins bind SDS in a ratio of 1.4 grams SDS to 1 gram protein. The charges intrinsic to the protein become insignificant compared to the overall negative charge provided by the bound SDS. The charge to mass ratio is essentially the same for each protein and will migrate in the gel based only on protein size. Typical Working Concentration: > 10 mg SDS/mg protein Typical Buffer Compositions: SDS Electrophoresis
    [Show full text]
  • Sodium Dodecyl Sulfate-Coated Alumina and C18 Cartridge for The
    J. Braz. Chem. Soc., Vol. 19, No. 8, 1523-1530, 2008. Printed in Brazil - ©2008 Sociedade Brasileira de Química 0103 - 5053 $6.00+0.00 Article Sodium Dodecyl Sulfate-Coated Alumina and C18 Cartridge for the Separation and Preconcentration of Cationic Surfactants Prior to their Quantitation by Spectrophotometric Method Mohammad Ali Karimi,*,a,b Reza Behjatmanesh-Ardakani,b Ali Aghaei Goudi b and Sara Zali b aDepartment of Chemistry, Faculty of Science, Payame Noor University (PNU), Sirjan, Iran bDepartment of Chemistry, Faculty of Science, Payame Noor University (PNU), Ardakan, Iran Um novo método de extração em fase sólida foi desenvolvido para separar e pré-concentrar traços de tensoativos catiônicos, tais como, brometo de dodeciltrimetilamônio (DTAB), brometo de cetiltrimetilamônio (CTAB) e cloreto de cetilpiridínio (CPC). Esse método é baseado na sorção do tensoativo aniônico (AS−), dodecilssulfato de sódio (SDS), sobre a superfície de γ-alumina, + enquanto um cartucho C18 é utilizado para a pré-concentração dos tensoativos catiônicos (CS ). O método espectrofotométrico, utilizado para a determinação dos tensoativos catiônicos, baseia-se na competição entre o corante catiônico, azul de metileno (MB+), e o CS+, para associação e formação do complexo SDS. O íon complexo formado (MB+) pode ser quantitativamente substituído pelo CS+, levando a um aumento da absorvância medida em 662 nm. Foram estabelecidas ótimas condições experimentais para a separação, pré-concentração e determinação dos tensoativos catiônicos. Sob essas condições otimizadas, realizou-se a pré-concentração (2×) e os resultados mostraram que a determinação do CPC, DTAB e CTAB poderia ser realizada nas faixas de concentração de 1×10-5-2×10-4, 4×10-5-5×10-4 and 5×10-5-5×10-4 mol L-1, respectivamente.
    [Show full text]
  • Sodium Lauryl Sulfate 1 Sodium Lauryl Sulfate
    Sodium lauryl sulfate 1 Sodium lauryl sulfate Sodium dodecyl sulfate Identifiers [1] CAS number 151-21-3 [2] ATC code A06 AG11 Properties Molecular formula NaC H SO 12 25 4 Molar mass 288.38 g mol−1 Density 1.01 g/cm³ Melting point 206 °C [3] (what is this?) (verify) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox references Sodium lauryl sulfate (SLS), sodium laurilsulfate or sodium dodecyl sulfate (SDS or NaDS) (C H SO Na) is 12 25 4 an anionic surfactant used in many cleaning and hygiene products. The molecule has a tail of 12 carbon atoms, attached to a sulfate group, giving the molecule the amphiphilic properties required of a detergent. SLS is a highly effective surfactant and is used in any task requiring the removal of oily stains and residues. For example, it is found in higher concentrations with industrial products including engine degreasers, floor cleaners, and car wash soaps. It is used in lower concentrations with toothpastes, shampoos, and shaving foams. It is an important component in bubble bath formulations for its thickening effect and its ability to create a lather. Research showed that SLS is not carcinogenic when either applied directly to skin or consumed.[4] It has however been shown to irritate the skin of the face with prolonged and constant exposure (more than an hour) in young adults.[5] A clinical study found SLS toothpaste caused a higher frequency of aphthous ulcers than both cocoamidopropyl betaine or a detergent-free paste, on 30 patients with frequent occurrences of such ulcers.[6] A clinical study comparing toothpastes with and without SLS found that it had no significant effect on ulcer patterns.[7] Sodium lauryl sulfate 2 Applications SLS is a highly effective surfactant and is used in any task requiring the removal of oily stains and residues.
    [Show full text]
  • Hazard Communication Chemical Inventory Form
    Hazard Communication Chemical Inventory Form ESTIM. CAS STATE QTY. USAGE ROOM SDS DATE OF CHEMICAL NAME COMMON NAME MANUFACTURER NUMBER S,L,G ON HAND PER YEAR CAMPUS NO. DEPARTMENT ? INV. 90wGear Oil NAPA L 5 gal 1 Gal AVC Auto shop Facilities Y 4/2/2018 Acetylene Gas Airgas USA G 33 cu ft 4 cu ft AVC Auto shop Facilities Y 4/2/2018 Antifreeze (Ethylene Glycol) NAPA L 1 gal 2 Gal AVC Auto shop Facilities Y 4/2/2018 Brakleen CRC Industries G 8 cans 12 Cans AVC Auto shop Facilities Y 4/2/2018 CBC Plus Bowl Cleaner ECOLAB L 60 72 AVC Auto shop Facilities Y 4/2/2018 DOT3 Brake Fluid NAPA Mixture L 1 QT 1 QT AVC Auto shop Facilities Y 4/2/2018 Hydraulic Oil NAPA L 10 gal 4 gal AVC Auto shop Facilities Y 4/2/2018 Motor Oil NAPA L 48 Qt 32 Qt AVC Auto shop Facilities Y 4/2/2018 Oxygen Gas Airgas USA G 33 cu ft 10 cu ft AVC Auto shop Facilities Y 4/2/2018 Toluidine Blue 2% Carolina 92-31-9 L 20mL 0mL AVC B112 Science SDS 1/22/2018 Isopropyl Alcohol 2-Propanol, Isopropanol JT Baker(Avantor) 67-63-0 L 75mL 5mL AVC B112 Science SDS 1/22/2018 Ammonium Molybdate ammonium molybdate(VI), tetrahydrate, molybdicFlinn acid 12027-67-7 S 15g 10g AVC B112 Science SDS 1/22/2018 Ammonium Chloride ammonium muriate, sal ammoniac Flinn 12125-02-9 S 40g 5g AVC B112 Science SDS 1/22/2018 Ethylene Glycol Anti-Freeze JT Baker(Avantor) 107-21-1 L 1.25L 10mL AVC B112 Science SDS 1/22/2018 Sodium Bicarbonate Baking Soda VWR (Wards) 144-55-8 S 1,020g 10g AVC B112 Science No 1/22/2018 Sodium Borate Borax VWR 1303-96-4 S 225g 10g AVC B112 Science SDS 1/22/2018 Calcium Metal
    [Show full text]
  • PROVERA Medroxyprogesterone Acetate Tablets 2.5Mg, 5Mg, 10Mg, 100 Mg, 200 Mg Tablets
    PROVERA Medroxyprogesterone acetate tablets 2.5mg, 5mg, 10mg, 100 mg, 200 mg tablets What is in this leaflet establish a regular menstrual breast cancer or breast lumps cycle not diagnosed by your doctor This leaflet answers some common bleeding or discharge from questions about PROVERA. It does certain types of cancer including your nipples not contain all the available cancer of the breast, kidney and information. It does not take the endometrium (the lining of the miscarriage place of talking to your doctor or womb). pharmacist. cancer of the womb or ovary PROVERA, in combination with an uncontrolled high blood estrogen containing medicine, is All medicines have risks and pressure. benefits. Your doctor has weighed used to relieve symptoms of the risks of you taking PROVERA menopause in women with an intact Do not take PROVERA if you are against the benefits it is expected to uterus. This is called hormone pregnant or intend to become have for you. replacement therapy (HRT). pregnant. PROVERA is used to protect the If you have any concerns about lining of the uterus while the PROVERA may affect your taking this medicine, ask your estrogens relieve the symptoms of developing baby if you take it doctor or pharmacist. Keep this menopause. PROVERA is not during pregnancy. leaflet with your medicine. suitable as a HRT treatment in women who have undergone a Do not take PROVERA if the You may need to read it again. hysterectomy. packaging is torn or shows signs of tampering. Do not take Your doctor may have prescribed PROVERA after the expiry date What PROVERA is PROVERA for another purpose.
    [Show full text]
  • Liquid Spray Formulations for Buccal Delivery of Cannabinoids
    (19) TZZ_¥__T (11) EP 1 361 864 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/08 (2006.01) A61K 9/107 (2006.01) 04.12.2013 Bulletin 2013/49 A61K 36/185 (2006.01) (21) Application number: 02712063.3 (86) International application number: PCT/GB2002/000620 (22) Date of filing: 14.02.2002 (87) International publication number: WO 2002/064109 (22.08.2002 Gazette 2002/34) (54) LIQUID SPRAY FORMULATIONS FOR BUCCAL DELIVERY OF CANNABINOIDS FLÜSSIGE SPRAY FORMULIERUNGEN ZUR BUCCALEN VERABREICHUNG VON CANNABINOIDEN PREPARATIONS DE SPRAY LIQUIDE POUR L’ADMINISTRATION BUCCALE DE CANNABINOIDES (84) Designated Contracting States: (74) Representative: Schiller, Dominic Christopher et AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU al MC NL PT SE TR Harrison Goddard Foote LLP Designated Extension States: 4th Floor, Merchant Exchange RO SI 17-19 Whitworth Street West Manchester M1 5WG (GB) (30) Priority: 14.02.2001 GB 0103638 30.03.2001 US 280044 P (56) References cited: 05.04.2001 US 827158 WO-A-00/25127 WO-A-01/66089 11.05.2001 GB 0111597 WO-A-95/25504 WO-A1-02/32420 07.09.2001 GB 0121715 WO-A1-02/069993 US-A- 3 560 625 12.09.2001 US 951022 • EITAN ALHANATY; ET AL.: "Osmotic fragility of (43) Date of publication of application: liposomes as affected by antihemolytic 19.11.2003 Bulletin 2003/47 compounds" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 339, no. 1, 1974, pages 146-155, (60) Divisional application: XP008008726 10180611.5 / 2 286 793 • PATRICIA S.
    [Show full text]
  • Student Members of the American Chemical Society Poster Presentation Event November 6, 2020 5:30 - 7:00 Pm Stonecipher Lecture Hall
    Student Members of the American Chemical Society Poster Presentation Event November 6, 2020 5:30 - 7:00 pm Stonecipher Lecture Hall Author: Brooke Underwood*, Courtney LaPointe, Dr. Jeffrey Boles Contact information: [email protected] Title: Liquid-liquid extraction and ultraviolet visible spectroscopy methods for distinguishing between hemp and marijuana Abstract: In December 2018, cannabis containing less than 0.3% tetrahydrocannabinol (THC), otherwise known as hemp, became legalized due to passage of the Farm Bill (1). This creates problems for law enforcement since current presumptive test kits either 1) don’t work at all or 2) work somewhat in differentiating between legal and illegal hemp crops. This problem exists because most hemp crops and hemp products contain low levels of THC and the carboxylated form, THCA. Our approach involves the advancement of an efficient, mobile, liquid-liquid extraction (LLE) that provides presumptive, qualitative forensic evidence of the chemical extract of a bud or other plant material. This research is focused on developing a kit that functions in a similar manner to NIK kits, commonly used by law enforcement, where all components of the kit are contained within a bag. The current NIK kit for Marijuana provides a false positive when Hemp is placed in the bag, thus creating the need for a more reliable test (2). The evidence would later be sent to a crime lab for definitive analysis and quantitation of THC by ultraviolet-visible spectroscopy (UV-vis). This research has focused on the utilization of liquid-liquid extraction techniques and commercially available stains. The methods presented are rapid (requiring no more than five to six minutes to complete).
    [Show full text]
  • Sodium Laurilsulfate Used As an Excipient
    9 October 2017 EMA/CHMP/351898/2014 corr. 1* Committee for Human Medicinal Products (CHMP) Sodium laurilsulfate used as an excipient Report published in support of the ‘Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use’ (EMA/CHMP/606830/2017) * Deletion of the E number. Please see the corrected Annex for further details. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Sodium laurilsulfate used as an excipient Table of contents Executive summary ..................................................................................... 3 Introduction ................................................................................................ 4 Scientific discussion .................................................................................... 4 1. Characteristics ....................................................................................... 4 1.1 Category (function) ............................................................................................. 4 1.2 Properties........................................................................................................... 4 1.3 Use in medicinal products ..................................................................................... 5 1.4 Regulatory
    [Show full text]
  • United States Patent (19) 11) Patent Number: 5,073,374 Mccarty 45 Date of Patent: Dec
    United States Patent (19) 11) Patent Number: 5,073,374 McCarty 45 Date of Patent: Dec. 17, 1991 54 FAST DISSOLVING BUCCAL TABLET 1380171 1/1975 United Kingdom . 21888.43 10/1987 United Kingdom . 75 Inventor: John A. McCarty, Biscayne Park, 04342 7/1987 World Int. Prop. O. .......... 424/435 Fla. OTHER PUBLICATIONS 73 Assignee: Schering Corporation, Kenilworth, N. Kornbloom and Stoopak, J. Pharm. Sci., 62:43-49 (1973). (21 Appl. No.: 278,099 Kahn and Rooke, Mfg. Chemist & Aerosol News, pp. 22 Filed: Nov. 30, 1988 25-26 (Jan. 1976). 51 int. Cl. ........................ A61K9/20: A61K 47/00 Kahn and Rooke, J. Pharm. Pharmacol., 28:633-636 52 U.S. Cl. .................................... 424/435; 424/434; (1976). 424/464; 424/465; 514/777 Primary Examiner-Thurman K. Page 58 Field of Search ................ 424/434, 435, 465,499 Assistant Examiner-James M. Spear 56 References Cited Attorney, Agent, or Firm-Anita W. Magatti; James R. Nelson U.S. PATENT DOCUMENTS 4,059,686 1/1977 Tanaka et al. ........................ 424/19 57 ABSTRACT 4,226,848 10/1980 Naggi et al. .......................... 424/19 A fast dissolving buccal tablet for administering a medi 4,292.299 9/1981 Suzuki et al. ......................... 424/16 4,572,832 2/1986 Kigasawa et al. .................... 424/19 canent includes the active ingredient, a lubricant and a 4,755,386 7/1988 Hsiao et al. ......................... 424/435 water soluble sugar, such as sorbitol, combined such that the buccal tablet dissolves in about one minute. FOREIGN PATENT DOCUMENTS 275853 10/1973 France . 10 Claims, No Drawings 5,073,374 1 2 the patient from swallowing the dosage form.
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]
  • Microflex Gloves Chemical Compatibility Chart
    1 1 1 2 2 3 1 CAUTION (LATEX): This product contains natural rubber 2 CAUTION (NITRILE: MEDICAL GRADE): Components used 3 CAUTION (NITRILE: NON-MEDICAL GRADE)): These latex (latex) which may cause allergic reactions. Safe use in making these gloves may cause allergic reactions in gloves are for non-medical use only. They may NOT be of this glove by or on latex sensitized individuals has not some users. Follow your institution’s policies for use. worn for barrier protection in medical or healthcare been established. applications. Please select other gloves for these applications. Components used in making these gloves may cause allergic reactions in some users. Follow your institution’s policies for use. For single use only. NeoPro® Chemicals NeoPro®EC Ethanol ■NBT Ethanolamine (99%) ■NBT Ether ■2 Ethidium bromide (1%) ■NBT Ethyl acetate ■1 Formaldehyde (37%) ■NBT Formamide ■NBT Gluteraldehyde (50%) ■NBT Test Method Description: The test method uses analytical Guanidine hydrochloride ■NBT equipment to determine the concentration of and the time at which (50% ■0 the challenge chemical permeates through the glove film. The Hydrochloric acid ) liquid challenge chemical is collected in a liquid miscible chemical Isopropanol ■NBT (collection media). Data is collected in three separate cells; each cell Methanol ■NBT is compared to a blank cell which uses the same collection media as both the challenge and Methyl ethyl ketone ■0 collection chemical. Methyl methacrylate (33%) ■0 Cautionary Information: These glove recommendations are offered as a guide and for reference Nitric acid (50%) ■NBT purposes only. The barrier properties of each glove type may be affected by differences in material Periodic acid (50%) ■NBT thickness, chemical concentration, temperature, and length of exposure to chemicals.
    [Show full text]
  • Disposal of Solid Chemicals in the Normal Trash
    Disposal of Solid Chemicals in the Normal Trash Many solid chemicals can be safety discarded into the normal trash, provided they are in containers that are not broken or cracked and have tightly fitting caps. These chemicals are considered acceptable for ordinary disposal because they display none of the properties of hazardous waste, are of low acute toxicity, and have not been identified as having any chronic toxic effects as summarized in the National Institute of Occupational Safety and Health (NIOSH) “Registry of Toxic Effects of Chemical Substances”. Examples of chemicals acceptable for disposal as regular trash are listed below. To dispose of these chemicals, place the containers in a box lined with a plastic bag, tape the top of the box shut, write “Normal Trash” on the box and then place the box next to the lab trash container. Only solid forms of these chemicals can be disposed in this manner. Any questions about these chemicals or other chemicals that may be disposed of in the normal trash should be directed to the Hazardous Materials Technician (610) 330-5225. Chemicals Generally Acceptable for Disposal as Regular Trash Acacia powder, gum Detergent (most) Methyl salicylate Sodium carbonate arabic Cation exchange resins Methylene blue Sodium chloride Acid, Ascorbic Chromatographic Methyl stearate Sodium citrate Acid, Benzoic absorbents Nutrient agar Sodium dodecyl sulfate Acid, Boric Crystal violet Octacosane (SDS) Acid, Casamind Dextrin Parafin Sodium formate Acid, Citric Dextrose Pepsin Sodium iodide Acid, Lactic Diatomaceous
    [Show full text]